DORDA Rechtsanwälte GmbH’s Post

We’re headed to California! Javara Co-founder and Chief Legal Officer Linda McCarty, JD has been invited to speak at the McDermott Will & Emery Pharma and Medtech Services Investment Summit THIS Thursday, May 2th in San Francisco. “Clinical Trial Site Management Organizations” is a session you won’t want to miss. More details below! #javara #javaralive #clinicalresearch #clinicaltrials #PharmaInvest2024 #conferences

👉 Meet Mari Korsten, Barend Bouma and Ayse Burcu Sucuka during the Figon Dutch Medicin Days 20 & 21 September in Oss.   👉 Mari and Barend will share on how to contribute daily to develop an authorized medicine as the ultimate goal. How can you execute essential steps of your strategy, day by day?   👉 These steps include the design of your preclinical R&D program and during each aspect, one of the essentials is assessing whether and how your IP should be secured by filing patent applications on the right time. This, for example, for the purpose of being able to raise the funds required for executing (pre)clinical trials and more in general, having the resources for running your business.   👉 In addition, IP protection is of utmost relevance for building a viable business model, also once market authorization for your new therapy is the crown on top of all your efforts for years.   #IP #intellectualproperty #viable #businessmodel #innovation

A great pairing if you ask me! Two of Cooley's most prolific attorneys talk to Law360 about the #Cooley difference. Since facilitating the first biotech IPO in history, our attorneys have remained at the forefront of the innovation ecosystem, expertly guiding clients from R&D to Commercialization and beyond, and everything in between. Check it out... cc: Marc Recht & Chad Shear

In an article spotlighting Cooley’s 2023 Life Sciences Group of the Year recognition, Law360 spoke with partners Marc Recht and Chad Shear, as they discussed how the firm's longstanding biotech industry leadership, collaborative workplace culture and breadth of practice play key roles in Cooley's accomplishments across the life sciences ecosystem. Subscribers can read more with the link below. Cooley's global life sciences practice spans corporate, litigation, regulatory and intellectual property capabilities, with almost 280 partners, associates, paralegals and other legal professionals attached to life sciences work of some kind across all 19 offices. Learn more here: https://bit.ly/49Kvv8f #lifesciences #leadership #biotech #TeamCooley

🤝 Navigating Collaborative Challenges: Lessons from CAT vs Abbott 🤝 Collaborations are the cornerstone of innovation, but they often tread the path of complexity. Take the case of CAT v Abbott, a legal dispute that highlighted the intricate challenges faced when partners encounter differing interpretations of collaboration agreements. 🔍 Dissecting the Disagreement 🔍 At the heart of the dispute was the intellectual property agreement between Cambridge Antibody Technology (CAT) and Abbott, concerning the development of HUMIRA- a ground-breaking anti-TNF-a monoclonal antibody drug. The disagreement arose over the interpretation of a crucial royalty-sharing clause, igniting a legal battle. 🔗 Patents and Perspectives 🔗 CAT had licensed 2 pivotal patents to Abbott. Abbott believed that everything related to CAT's Winter 2 and McCafferty patents should be part of the royalty-sharing deal. CAT thought only things directly linked to their Winter 2 and McCafferty work should count. This difference in opinions played a major role in the case's outcome. ⚖️ The Verdict and Its Pillars ⚖️ The court's verdict, delivered by Justice Laddie, revolved around 2 critical factors. 1️⃣ language of the Agreement itself, which aligned with CAT's interpretation. 2️⃣ logical commercial considerations, given CAT's limited involvement beyond its initial technologies. 🤔 Resolution? 🤔 💰 Abbott agreed to pay $255M plus 5 annual $9.375M payments for HUMIRA rights. 💰 CAT secured a 2.688% net royalty on HUMIRA sales. 💡 Beyond the Courtroom: Real-World Ripples 💡 The implications of this ruling rippled beyond legal realms. CAT's aspirations to acquire Oxford GlycoSciences (OGS) through a share-for-share exchange were hindered by a precipitous drop in CAT's share price due to the dispute. This compelled CAT to shift gears, prioritizing organic growth over acquisitions. 🚀 Lessons for Collaborative Endeavours🚀 CAT v Abbott underscores that collaborations, though potent for innovation, tangle in complexity. Untangling demands balance—clear contracts, legal grasp, and unwavering commitment to the ultimate goal! 💪 #CollaborationComplexities #InnovationJourney #CATvAbbottInsights #RegulatoryAffairs #IPR #Pharmaceutical #PatentLaw

The law firm ARQIS, with the team of Jörn-Christian Schulze (pictured), together with the law firm Franzosi Dal Negro Setti, with the lawyers Francesco Setti and Stefano Giberti, managed the transaction of the global dossier ownership and exclusive licence to the Proctosedyl® trademark in Italy from Bayer to Karo Healthcare. “This acquisition adds a reliable brand that addresses an often overlooked category with untapped potential. We are excited about the opportunity to improve access to reliable treatments for Italian consumers and add further scale and reach to our business in Italy,” says Matt Roberts, CC Rewarding expertise in life sciences and acquisitions. Read the full article >> https://lnkd.in/ddUimKQv #Legalcommunitygermany #legaladvisor #acquisition

Cooley LLP partners Simon Amies, Thomas Goodman, Frances Stocks Allen and Courtney Tallman Thorne recently got together to examine what they believe 2024 has in store for UK and European Union biopharma companies. Get their insights via an on-demand recording of the conversation with the link below. #biopharma #lifesciences #webinar #EU #UK #thoughtleadership

Cooley LLP partners Simon Amies, Thomas Goodman, Frances Stocks Allen and Courtney Tallman Thorne recently got together to examine what they believe 2024 has in store for UK and European Union biopharma companies. Get their insights via an on-demand recording of the conversation with the link below. #biopharma #lifesciences #webinar #EU #UK #thoughtleadership

Four law firms have facilitated ImmuneOnco Biopharmaceuticals’ HKD319 million (USD40.7 million) IPO on the HKEX, breaking a 50-day hiatus in listings on the Hong Kong bourse. Liu Yiming and Michael Yu led Cooley LLP’s team advising ImmuneOnco on Hong Kong and US law, with support from Xander Lee, Francis Wheeler and Eric Blanchard. JunHe LLP advised the issuer on PRC law, and PRC and US intellectual property law. Locke Lord assisted JunHe. Kirkland & Ellis acted as Hong Kong and US counsel to the joint sponsors, Morgan Stanley and CICC. Lu Mengyu and Samantha Peng led the team, with the assistance of Anne Kim and Kim Kaufman. Jingtian & Gongcheng acted as PRC counsel to the joint sponsors. Click Law.asia for more information. 📲Sign up for the latest updates in the legal industry: https://lnkd.in/g3brrPdM #lawdotasia #cblj #ablj #iblj #china #ipo #prclaw #inhousecounsel #business #legaladvice #lawfirms #lawyers #legal #law